The market expects Organon (OGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is ...

What Happened? A number of stocks jumped in the afternoon session after investor sentiment improved on renewed optimism that ...

BofA lowered the firm’s price target on Organon (OGN) to $11 from $15 and keeps an Underperform rating on the shares. The firm, in its preview ...

Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Organon (OGN – Research Report) today and set a price target of ...

Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of Labor ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

Access our full analysis report here, it’s free. Branded Pharmaceuticals company Organon (NYSE:OGN) jumped 7%. Is now the time to buy Organon? Access our full analysis report here, it’s free.